{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T18:16:10Z","timestamp":1775499370475,"version":"3.50.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,25]]},"DOI":"10.7759\/cureus.51089","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T06:07:34Z","timestamp":1703570854000},"source":"Crossref","is-referenced-by-count":3,"title":["Current Evidence and Expert Opinion on Thromboprophylaxis After Total Knee and Hip Replacement"],"prefix":"10.7759","author":[{"given":"Bharat S","family":"Mody","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuj","family":"Wadhwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronen","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shwetha","family":"Echila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s43465-020-00251-y","article-title":"India joining the world of hip and knee registries: present status-a leap forward","volume":"55","author":"Vaidya SV","year":"2021","unstructured":"Vaidya SV, Jogani AD, Pachore JA, Armstrong R, Vaidya CS. India joining the world of hip and knee registries: present status-a leap forward. Indian J Orthop. 2021, 55:46-55. 10.1007\/s43465-020-00251-y","journal-title":"Indian J Orthop"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000369","article-title":"Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in elderly elective postarthroplasty patients","volume":"26","author":"Pathak R","year":"2015","unstructured":"Pathak R, Giri S, Karmacharya P, et al.. Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in elderly elective postarthroplasty patients. Blood Coagul Fibrinolysis. 2015, 26:934-9. 10.1097\/MBC.0000000000000369","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2404","article-title":"Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Falck-Ytter Y","year":"2012","unstructured":"Falck-Ytter Y, Francis CW, Johanson NA, et al.. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012, 141:e278S-325S. 10.1378\/chest.11-2404","journal-title":"Chest"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1568875","article-title":"Major bleeding and case fatality rate with the direct oral anticoagulants in orthopedic surgery: a systematic review and meta-analysis","volume":"42","author":"Riva N","year":"2016","unstructured":"Riva N, Dentali F, Permunian ET, Ageno W. Major bleeding and case fatality rate with the direct oral anticoagulants in orthopedic surgery: a systematic review and meta-analysis. Semin Thromb Hemost. 2016, 42:42-54. 10.1055\/s-0035-1568875","journal-title":"Semin Thromb Hemost"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2017.04.010","article-title":"Low-molecular-weight heparin and the relative risk of surgical site bleeding complications: results of a systematic review and meta-analysis of randomized controlled trials of venous thromboprophylaxis in patients after total joint arthroplasty","volume":"32","author":"Suen K","year":"2017","unstructured":"Suen K, Westh RN, Churilov L, Hardidge AJ. Low-molecular-weight heparin and the relative risk of surgical site bleeding complications: results of a systematic review and meta-analysis of randomized controlled trials of venous thromboprophylaxis in patients after total joint arthroplasty. J Arthroplasty. 2017, 32:2911-2919.e6. 10.1016\/j.arth.2017.04.010","journal-title":"J Arthroplasty"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2015.02.008","article-title":"Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: a meta-analysis of 6 randomized clinical trials","volume":"135","author":"Ma G","year":"2015","unstructured":"Ma G, Zhang R, Wu X, Wang D, Ying K. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: a meta-analysis of 6 randomized clinical trials. Thromb Res. 2015, 135:816-22. 10.1016\/j.thromres.2015.02.008","journal-title":"Thromb Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2015.10.009","article-title":"Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis","volume":"136","author":"Feng W","year":"2015","unstructured":"Feng W, Wu K, Liu Z, et al.. Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis. Thromb Res. 2015, 136:1133-44. 10.1016\/j.thromres.2015.10.009","journal-title":"Thromb Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2016.09.033","article-title":"Safety and efficacy of new anticoagulants for the prevention of venous thromboembolism after hip and knee arthroplasty: a\u00a0meta-analysis","volume":"32","author":"Venker BT","year":"2017","unstructured":"Venker BT, Ganti BR, Lin H, Lee ED, Nunley RM, Gage BF. Safety and efficacy of new anticoagulants for the prevention of venous thromboembolism after hip and knee arthroplasty: a\u00a0meta-analysis. J Arthroplasty. 2017, 32:645-52. 10.1016\/j.arth.2016.09.033","journal-title":"J Arthroplasty"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/17453674.2017.1361131","article-title":"Comparative efficacy and safety of anticoagulants for prevention of venous thromboembolism after hip and knee arthroplasty","volume":"88","author":"Hur M","year":"2017","unstructured":"Hur M, Park SK, Koo CH, et al.. Comparative efficacy and safety of anticoagulants for prevention of venous thromboembolism after hip and knee arthroplasty. Acta Orthop. 2017, 88:634-41. 10.1080\/17453674.2017.1361131","journal-title":"Acta Orthop"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12471","article-title":"Direct oral anticoagulants vs. enoxaparin for prevention of venous thromboembolism following orthopedic surgery: a dose-response meta-analysis","volume":"10","author":"Boyd RA","year":"2017","unstructured":"Boyd RA, DiCarlo L, Mandema JW. Direct oral anticoagulants vs. enoxaparin for prevention of venous thromboembolism following orthopedic surgery: a dose-response meta-analysis. Clin Transl Sci. 2017, 10:260-70. 10.1111\/cts.12471","journal-title":"Clin Transl Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20180423","article-title":"Comparison of efficiency and safety of rivaroxaban, apixaban and enoxaparin for thromboprophylaxis after arthroplastic surgery: a meta-analysis","volume":"38","author":"Yu Z","year":"2018","unstructured":"Yu Z, Shan P, Yang X, Lou XJ. Comparison of efficiency and safety of rivaroxaban, apixaban and enoxaparin for thromboprophylaxis after arthroplastic surgery: a meta-analysis. Biosci Rep. 2018, 38:10.1042\/BSR20180423","journal-title":"Biosci Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/1179545X17704660","article-title":"Thromboprophylaxis with apixaban in patients undergoing major orthopedic surgery: meta-analysis and trial-sequential analysis","volume":"10","author":"Caldeira D","year":"2017","unstructured":"Caldeira D, Rodrigues FB, Pinto FJ, Ferreira JJ, Costa J. Thromboprophylaxis with apixaban in patients undergoing major orthopedic surgery: meta-analysis and trial-sequential analysis. Clin Med Insights Blood Disord. 2017, 10:1179545X17704660. 10.1177\/1179545X17704660","journal-title":"Clin Med Insights Blood Disord"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski P","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al.. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016, 37:2129-200. 10.1093\/eurheartj\/ehw128","journal-title":"Eur Heart J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.114.303400","article-title":"Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty","volume":"35","author":"Messerschmidt C","year":"2015","unstructured":"Messerschmidt C, Friedman RJ. Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty. Arterioscler Thromb Vasc Biol. 2015, 35:771-8. 10.1161\/ATVBAHA.114.303400","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref15","article-title":"Home prophylactic warfarin anticoagulation program after hip and knee arthroplasty","volume":"42","author":"Schuringa P","unstructured":"Schuringa P, Yen D.  Home prophylactic warfarin anticoagulation program after hip and knee arthroplasty. Can J Surg.  199, 42:360-2.","journal-title":"Can J Surg"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1185\/030079908x242746","article-title":"Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty","volume":"24","author":"Friedman RJ","year":"2008","unstructured":"Friedman RJ, Gallus AS, Cushner FD, Fitzgerald G, Anderson FA Jr. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin. 2008, 24:87-97. 10.1185\/030079908x242746","journal-title":"Curr Med Res Opin"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-062209-095159","article-title":"Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism","volume":"62","author":"Eriksson BI","year":"2011","unstructured":"Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med. 2011, 62:41-57. 10.1146\/annurev-med-062209-095159","journal-title":"Annu Rev Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.5435\/00124635-201112000-00001","article-title":"The new AAOS clinical practice guidelines on venous thromboembolic prophylaxis: how to adapt them to your practice","volume":"19","author":"Lieberman JR","year":"2011","unstructured":"Lieberman JR. The new AAOS clinical practice guidelines on venous thromboembolic prophylaxis: how to adapt them to your practice. J Am Acad Orthop Surg. 2011, 19:717-21. 10.5435\/00124635-201112000-00001","journal-title":"J Am Acad Orthop Surg"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kearon C","year":"2012","unstructured":"Kearon C, Akl EA, Comerota AJ, et al.. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012, 141:e419S-96S. 10.1378\/chest.11-2301","journal-title":"Chest"},{"key":"ref20","article-title":"Prevention and management of venous thromboembolism: a National Clinical Guideline","author":"Scottish Intercollegiate Guidelines Network (SIGN)","year":"2014","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN). Prevention and management of venous thromboembolism: a National Clinical Guideline. Scottish Intercollegiate Guidelines Network, Edinburgh; 2014."},{"key":"ref21","article-title":"Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism","author":"National Guideline Centre (UK)","year":"2018","unstructured":"National Guideline Centre (UK). Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism\r\n. National Institute for Health and Care Excellence (NICE), London; 2018."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/EJA.0000000000000729","article-title":"European guidelines on perioperative venous thromboembolism prophylaxis: Executive summary","volume":"35","author":"Afshari A","year":"2018","unstructured":"Afshari A, Ageno W, Ahmed A, et al.. European guidelines on perioperative venous thromboembolism prophylaxis: Executive summary. Eur J Anaesthesiol. 2018, 35:77-83. 10.1097\/EJA.0000000000000729","journal-title":"Eur J Anaesthesiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000975","article-title":"American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients","volume":"3","author":"Anderson DR","year":"2019","unstructured":"Anderson DR, Morgano GP, Bennett C, et al.. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019, 3:3898-944. 10.1182\/bloodadvances.2019000975","journal-title":"Blood Adv"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.91B5.21939","article-title":"The incidence of fatal pulmonary embolism after primary hip and knee replacement in a consecutive series of 4253 patients","volume":"91","author":"Cusick LA","year":"2009","unstructured":"Cusick LA, Beverland DE. The incidence of fatal pulmonary embolism after primary hip and knee replacement in a consecutive series of 4253 patients. J Bone Joint Surg Br. 2009, 91:645-8. 10.1302\/0301-620X.91B5.21939","journal-title":"J Bone Joint Surg Br"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/01.blo.0000201157.29325.f0","article-title":"Venous thromboembolism is rare with a multimodal prophylaxis protocol after total hip arthroplasty","volume":"444","author":"Gonz\u00e1lez Della Valle A","year":"2006","unstructured":"Gonz\u00e1lez Della Valle A, Serota A, Go G, Sorriaux G, Sculco TP, Sharrock NE, Salvati EA. Venous thromboembolism is rare with a multimodal prophylaxis protocol after total hip arthroplasty. Clin Orthop Relat Res. 2006, 444:146-53. 10.1097\/01.blo.0000201157.29325.f0","journal-title":"Clin Orthop Relat Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/01.blo.0000238822.78895.95","article-title":"The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty","volume":"452","author":"Lotke PA","year":"2006","unstructured":"Lotke PA, Lonner JH. The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty. Clin Orthop Relat Res. 2006, 452:175-80. 10.1097\/01.blo.0000238822.78895.95","journal-title":"Clin Orthop Relat Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712746","article-title":"Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty","volume":"378","author":"Anderson DR","year":"2018","unstructured":"Anderson DR, Dunbar M, Murnaghan J, et al.. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med. 2018, 378:699-707. 10.1056\/NEJMoa1712746","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2019.6108","article-title":"Clinical effectiveness and safety of aspirin for venous thromboembolism prophylaxis after total hip and knee replacement: a systematic review and meta-analysis of randomized clinical trials","volume":"180","author":"Matharu GS","year":"2020","unstructured":"Matharu GS, Kunutsor SK, Judge A, Blom AW, Whitehouse MR. Clinical effectiveness and safety of aspirin for venous thromboembolism prophylaxis after total hip and knee replacement: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2020, 180:376-84. 10.1001\/jamainternmed.2019.6108","journal-title":"JAMA Intern Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023055","article-title":"Efficacy and safety of aspirin and rivaroxaban for venous thromboembolism prophylaxis after total hip or knee arthroplasty: a protocol for meta-analysis","volume":"99","author":"Le G","year":"2020","unstructured":"Le G, Yang C, Zhang M, Xi L, Luo H, Tang J, Zhao J. Efficacy and safety of aspirin and rivaroxaban for venous thromboembolism prophylaxis after total hip or knee arthroplasty: a protocol for meta-analysis. Medicine (Baltimore). 2020, 99:e23055. 10.1097\/MD.0000000000023055","journal-title":"Medicine (Baltimore)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001305","article-title":"Comparable efficacy of 100 mg aspirin twice daily and rivaroxaban for venous thromboembolism prophylaxis following primary total hip arthroplasty: a randomized controlled trial","volume":"134","author":"Ren Y","year":"2021","unstructured":"Ren Y, Cao SL, Li Z, Luo T, Feng B, Weng XS. Comparable efficacy of 100 mg aspirin twice daily and rivaroxaban for venous thromboembolism prophylaxis following primary total hip arthroplasty: a randomized controlled trial. Chin Med J (Engl). 2021, 134:164-72. 10.1097\/CM9.0000000000001305","journal-title":"Chin Med J (Engl)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2016.04.004","article-title":"Aspirin as thromboprophylaxis in hip and knee arthroplasty: a\u00a0systematic review and meta-analysis","volume":"31","author":"An VV","year":"2016","unstructured":"An VV, Phan K, Levy YD, Bruce WJ. Aspirin as thromboprophylaxis in hip and knee arthroplasty: a\u00a0systematic review and meta-analysis. J Arthroplasty. 2016, 31:2608-16. 10.1016\/j.arth.2016.04.004","journal-title":"J Arthroplasty"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0656","article-title":"Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Geerts WH","year":"2008","unstructured":"Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008, 133:381S-453S. 10.1378\/chest.08-0656","journal-title":"Chest"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16010","article-title":"The National VTE Exemplar Centres Network response to implementation of updated NICE guidance: venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)","volume":"186","author":"Gee E","year":"2019","unstructured":"Gee E. The National VTE Exemplar Centres Network response to implementation of updated NICE guidance: venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89). Br J Haematol. 2019, 186:792-3. 10.1111\/bjh.16010","journal-title":"Br J Haematol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1302\/2058-5241.3.170018","article-title":"Thromboembolism prophylaxis in orthopaedics: an update","volume":"3","author":"Flevas DA","year":"2018","unstructured":"Flevas DA, Megaloikonomos PD, Dimopoulos L, Mitsiokapa E, Koulouvaris P, Mavrogenis AF. Thromboembolism prophylaxis in orthopaedics: an update. EFORT Open Rev. 2018, 3:136-48. 10.1302\/2058-5241.3.170018","journal-title":"EFORT Open Rev"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.5435\/00124635-201112000-00007","article-title":"Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty","volume":"19","author":"Mont MA","year":"2011","unstructured":"Mont MA, Jacobs JJ, Boggio LN, et al.. Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Am Acad Orthop Surg. 2011, 19:768-76. 10.5435\/00124635-201112000-00007","journal-title":"J Am Acad Orthop Surg"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.23750\/abm.v89i1.7121","article-title":"Aspirin for thromboprophylaxis in major orthopedic surgery: old drug, new tricks?","volume":"89","author":"Lippi G","year":"2018","unstructured":"Lippi G, Cervellin G. Aspirin for thromboprophylaxis in major orthopedic surgery: old drug, new tricks?. Acta Biomed. 2018, 89:31-3. 10.23750\/abm.v89i1.7121","journal-title":"Acta Biomed"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56090416","article-title":"An update on venous thromboembolism rates and prophylaxis in hip and knee arthroplasty in 2020","volume":"56","author":"Santana DC","year":"2020","unstructured":"Santana DC, Emara AK, Orr MN, et al.. An update on venous thromboembolism rates and prophylaxis in hip and knee arthroplasty in 2020. Medicina (Kaunas). 2020, 56:10.3390\/medicina56090416","journal-title":"Medicina (Kaunas)"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.99B11.BJJ-2017-0337.R2","article-title":"Aspirin and the prevention of venous thromboembolism following total joint arthroplasty: commonly asked questions","volume":"99-B","author":"Azboy I","year":"2017","unstructured":"Azboy I, Barrack R, Thomas AM, Haddad FS, Parvizi J. Aspirin and the prevention of venous thromboembolism following total joint arthroplasty: commonly asked questions. Bone Joint J. 2017, 99-B:1420-30. 10.1302\/0301-620X.99B11.BJJ-2017-0337.R2","journal-title":"Bone Joint J"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial","volume":"5","author":"Eriksson BI","year":"2007","unstructured":"Eriksson BI, Dahl OE, Rosencher N, et al.. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007, 5:2178-85. 10.1111\/j.1538-7836.2007.02748.x","journal-title":"J Thromb Haemost"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial","volume":"370","author":"Eriksson BI","year":"2007","unstructured":"Eriksson BI, Dahl OE, Rosencher N, et al.. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007, 370:949-56. 10.1016\/S0140-6736(07)61445-7","journal-title":"Lancet"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2008.01.132","article-title":"Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery","volume":"24","author":"Ginsberg JS","year":"2009","unstructured":"Ginsberg JS, Davidson BL, Comp PC, et al.. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009, 24:1-9. 10.1016\/j.arth.2008.01.132","journal-title":"J Arthroplasty"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-10-0679","article-title":"Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial","volume":"105","author":"Eriksson BI","year":"2011","unstructured":"Eriksson BI, Dahl OE, Huo MH, et al.. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011, 105:721-9. 10.1160\/TH10-10-0679","journal-title":"Thromb Haemost"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2010.03.021","article-title":"Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials","volume":"126","author":"Friedman RJ","year":"2010","unstructured":"Friedman RJ, Dahl OE, Rosencher N, et al.. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res. 2010, 126:175-82. 10.1016\/j.thromres.2010.03.021","journal-title":"Thromb Res"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-09-0601","article-title":"Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies","volume":"105","author":"Turpie AG","year":"2011","unstructured":"Turpie AG, Lassen MR, Eriksson BI, et al.. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost. 2011, 105:444-53. 10.1160\/TH10-09-0601","journal-title":"Thromb Haemost"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson BI","year":"2008","unstructured":"Eriksson BI, Borris LC, Friedman RJ, et al.. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008, 358:2765-75. 10.1056\/NEJMoa0800374","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"Kakkar AK","year":"2008","unstructured":"Kakkar AK, Brenner B, Dahl OE, et al.. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008, 372:31-9. 10.1016\/S0140-6736(08)60880-6","journal-title":"Lancet"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen MR","year":"2008","unstructured":"Lassen MR, Ageno W, Borris LC, et al.. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008, 358:2776-86. 10.1056\/NEJMoa076016","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"373","author":"Turpie AG","year":"2009","unstructured":"Turpie AG, Lassen MR, Davidson BL, et al.. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009, 373:1673-80. 10.1016\/S0140-6736(09)60734-0","journal-title":"Lancet"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.110.957712","article-title":"Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: results of separate pooled analyses of phase III multicenter randomized trials","volume":"3","author":"Huisman MV","year":"2010","unstructured":"Huisman MV, Quinlan DJ, Dahl OE, Schulman S. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes. 2010, 3:652-60. 10.1161\/CIRCOUTCOMES.110.957712","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e3675","article-title":"Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons","volume":"344","author":"G\u00f3mez-Outes A","year":"2012","unstructured":"G\u00f3mez-Outes A, Terleira-Fern\u00e1ndez AI, Su\u00e1rez-Gea ML, Vargas-Castrill\u00f3n E. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ. 2012, 344:e3675. 10.1136\/bmj.e3675","journal-title":"BMJ"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3325\/cmj.2010.51.113","article-title":"Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials","volume":"51","author":"Trkulja V","year":"2010","unstructured":"Trkulja V, Kolundzic R. Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials. Croat Med J. 2010, 51:113-23. 10.3325\/cmj.2010.51.113","journal-title":"Croat Med J"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.94B2.27850","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials","volume":"94","author":"Raskob GE","year":"2012","unstructured":"Raskob GE, Gallus AS, Pineo GF, Chen D, Ramirez LM, Wright RT, Lassen MR. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br. 2012, 94:257-64. 10.1302\/0301-620X.94B2.27850","journal-title":"J Bone Joint Surg Br"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013465","article-title":"Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty: a meta-analysis","volume":"97","author":"Huang HF","year":"2018","unstructured":"Huang HF, Li SS, Yang XT, Xie Q, Tian XB. Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty: a meta-analysis. Medicine (Baltimore). 2018, 97:e13465. 10.1097\/MD.0000000000013465","journal-title":"Medicine (Baltimore)"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-018-2215-3","article-title":"Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis","volume":"19","author":"Lu X","year":"2018","unstructured":"Lu X, Lin J. Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2018, 19:322. 10.1186\/s12891-018-2215-3","journal-title":"BMC Musculoskelet Disord"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-10-201205150-00421","article-title":"Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis","volume":"156","author":"Neumann I","year":"2012","unstructured":"Neumann I, Rada G, Claro JC, et al.. Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis. Ann Intern Med. 2012, 156:710-9. 10.7326\/0003-4819-156-10-201205150-00421","journal-title":"Ann Intern Med"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105438","article-title":"Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: a systematic review and a network meta-analysis","volume":"166","author":"Feng W","year":"2021","unstructured":"Feng W, Wang X, Huang D, Lu A. Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: a systematic review and a network meta-analysis. Pharmacol Res. 2021, 166:105438. 10.1016\/j.phrs.2021.105438","journal-title":"Pharmacol Res"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1038\/srep23726","article-title":"Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials","volume":"6","author":"Ning GZ","year":"2016","unstructured":"Ning GZ, Kan SL, Chen LX, Shangguan L, Feng SQ, Zhou Y. Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials. Sci Rep. 2016, 6:23726. 10.1038\/srep23726","journal-title":"Sci Rep"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1007\/s00402-017-2697-8","article-title":"A comparison of apixaban and dabigatran etexilate for thromboprophylaxis following hip and knee replacement surgery","volume":"137","author":"Mayer A","year":"2017","unstructured":"Mayer A, Schuster P, Fink B. A comparison of apixaban and dabigatran etexilate for thromboprophylaxis following hip and knee replacement surgery. Arch Orthop Trauma Surg. 2017, 137:797-803. 10.1007\/s00402-017-2697-8","journal-title":"Arch Orthop Trauma Surg"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2020.06.032","article-title":"A prospective cohort comparative study of rivaroxaban, dabigatran, and apixaban oral thromboprophylaxis in 2431 hip and knee arthroplasty patients: primary efficacy outcomes and safety profile","volume":"35","author":"Highcock AJ","year":"2020","unstructured":"Highcock AJ, As-Sultany M, Finley R, Donnachie NJ. A prospective cohort comparative study of rivaroxaban, dabigatran, and apixaban oral thromboprophylaxis in 2431 hip and knee arthroplasty patients: primary efficacy outcomes and safety profile. J Arthroplasty. 2020, 35:3093-8. 10.1016\/j.arth.2020.06.032","journal-title":"J Arthroplasty"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1186\/s43019-021-00093-4","article-title":"Which orally administered antithrombotic agent is most effective for preventing venous thromboembolism after total knee arthroplasty? A propensity score-matching analysis","volume":"33","author":"Jang S","year":"2021","unstructured":"Jang S, Shin WC, Song MK, Han HS, Lee MC, Ro DH. Which orally administered antithrombotic agent is most effective for preventing venous thromboembolism after total knee arthroplasty? A propensity score-matching analysis. Knee Surg Relat Res. 2021, 33:10. 10.1186\/s43019-021-00093-4","journal-title":"Knee Surg Relat Res"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1007\/s11999-017-5394-6","article-title":"Venous thromboembolism prophylaxis after TKA: aspirin, warfarin, enoxaparin, or factor Xa inhibitors?","volume":"475","author":"Bala A","year":"2017","unstructured":"Bala A, Huddleston JI 3rd, Goodman SB, Maloney WJ, Amanatullah DF. Venous thromboembolism prophylaxis after TKA: aspirin, warfarin, enoxaparin, or factor Xa inhibitors?. Clin Orthop Relat Res. 2017, 475:2205-13. 10.1007\/s11999-017-5394-6","journal-title":"Clin Orthop Relat Res"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13139","article-title":"Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis","volume":"46","author":"King DA","year":"2016","unstructured":"King DA, Pow RE, Dickison DM, Vale PR. Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis. Intern Med J. 2016, 46:1030-7. 10.1111\/imj.13139","journal-title":"Intern Med J"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099276","article-title":"Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteria","volume":"9","author":"Clemens A","year":"2014","unstructured":"Clemens A, Noack H, Brueckmann M, Lip GY. Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteria. PLoS One. 2014, 9:e99276. 10.1371\/journal.pone.0099276","journal-title":"PLoS One"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.10.011","article-title":"Twice- or once-daily dosing of direct oral anticoagulants, a systematic review and meta-analysis","volume":"197","author":"Mainbourg S","year":"2021","unstructured":"Mainbourg S, Cucherat M, Provencher S, et al.. Twice- or once-daily dosing of direct oral anticoagulants, a systematic review and meta-analysis. Thromb Res. 2021, 197:24-32. 10.1016\/j.thromres.2020.10.011","journal-title":"Thromb Res"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euu311","article-title":"Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence","volume":"17","author":"Vrijens B","year":"2015","unstructured":"Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace. 2015, 17:514-23. 10.1093\/europace\/euu311","journal-title":"Europace"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.115.303397","article-title":"Overview of the new oral anticoagulants: opportunities and challenges","volume":"35","author":"Yeh CH","year":"2015","unstructured":"Yeh CH, Hogg K, Weitz JI. Overview of the new oral anticoagulants: opportunities and challenges. Arterioscler Thromb Vasc Biol. 2015, 35:1056-65. 10.1161\/ATVBAHA.115.303397","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-021-01016-7","article-title":"Efficacy and safety of direct oral anticoagulants vs warfarin in patients with chronic kidney disease and dialysis patients: a systematic review and meta-analysis","volume":"41","author":"Chen HY","year":"2021","unstructured":"Chen HY, Ou SH, Huang CW, Lee PT, Chou KJ, Lin PC, Su YC. Efficacy and safety of direct oral anticoagulants vs warfarin in patients with chronic kidney disease and dialysis patients: a systematic review and meta-analysis. Clin Drug Investig. 2021, 41:341-51. 10.1007\/s40261-021-01016-7","journal-title":"Clin Drug Investig"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1177\/1753944717714921","article-title":"Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment","volume":"11","author":"Turpie AG","year":"2017","unstructured":"Turpie AG, Purdham D, Ciaccia A. Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment. Ther Adv Cardiovasc Dis. 2017, 11:243-56. 10.1177\/1753944717714921","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S88088","article-title":"Considerations for long-term anticoagulant therapy in patients with venous thromboembolism in the novel oral anticoagulant era","volume":"12","author":"Toth PP","year":"2016","unstructured":"Toth PP. Considerations for long-term anticoagulant therapy in patients with venous thromboembolism in the novel oral anticoagulant era. Vasc Health Risk Manag. 2016, 12:23-34. 10.2147\/VHRM.S88088","journal-title":"Vasc Health Risk Manag"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2018.06.024","article-title":"Systematic review of risk prediction scores for venous thromboembolism following joint replacement","volume":"168","author":"Kunutsor SK","year":"2018","unstructured":"Kunutsor SK, Beswick AD, Whitehouse MR, Blom AW. Systematic review of risk prediction scores for venous thromboembolism following joint replacement. Thromb Res. 2018, 168:148-55. 10.1016\/j.thromres.2018.06.024","journal-title":"Thromb Res"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12323","article-title":"What's new in VTE risk and prevention in orthopedic surgery","volume":"4","author":"Kahn SR","year":"2020","unstructured":"Kahn SR, Shivakumar S. What's new in VTE risk and prevention in orthopedic surgery. Res Pract Thromb Haemost. 2020, 4:366-76. 10.1002\/rth2.12323","journal-title":"Res Pract Thromb Haemost"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-2710","article-title":"Timing the first postoperative dose of anticoagulants: lessons learned from clinical trials","volume":"148","author":"Paikin JS","year":"2015","unstructured":"Paikin JS, Hirsh J, Chan NC, Ginsberg JS, Weitz JI, Eikelboom JW. Timing the first postoperative dose of anticoagulants: lessons learned from clinical trials. Chest. 2015, 148:587-95. 10.1378\/chest.14-2710","journal-title":"Chest"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.4103\/ija.IJA_734_18","article-title":"Novel reversal agents and laboratory evaluation for direct-acting oral anticoagulants (DOAC): an update","volume":"63","author":"Shah SB","year":"2019","unstructured":"Shah SB, Pahade A, Chawla R. Novel reversal agents and laboratory evaluation for direct-acting oral anticoagulants (DOAC): an update. Indian J Anaesth. 2019, 63:169-81. 10.4103\/ija.IJA_734_18","journal-title":"Indian J Anaesth"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.04.061","article-title":"Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants","volume":"77","author":"G\u00f3mez-Outes A","year":"2021","unstructured":"G\u00f3mez-Outes A, Alcubilla P, Calvo-Rojas G, Terleira-Fern\u00e1ndez AI, Su\u00e1rez-Gea ML, Lecumberri R, Vargas-Castrill\u00f3n E. Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants. J Am Coll Cardiol. 2021, 77:2987-3001. 10.1016\/j.jacc.2021.04.061","journal-title":"J Am Coll Cardiol"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2016.31.1.80","article-title":"Venous thromboembolism following hip and knee replacement arthroplasty in Korea: a nationwide study based on claims registry","volume":"31","author":"Lee S","year":"2016","unstructured":"Lee S, Hwang JI, Kim Y, Yoon PW, Ahn J, Yoo JJ. Venous thromboembolism following hip and knee replacement arthroplasty in Korea: a nationwide study based on claims registry. J Korean Med Sci. 2016, 31:80-8. 10.3346\/jkms.2016.31.1.80","journal-title":"J Korean Med Sci"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.89B6.18844","article-title":"Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry","volume":"89","author":"Warwick D","year":"2007","unstructured":"Warwick D, Friedman RJ, Agnelli G, Gil-Garay E, Johnson K, FitzGerald G, Turibio FM. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br. 2007, 89:799-807. 10.1302\/0301-620X.89B6.18844","journal-title":"J Bone Joint Surg Br"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/172644-current-evidence-and-expert-opinion-on-thromboprophylaxis-after-total-knee-and-hip-replacement","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:11:50Z","timestamp":1707509510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/172644-current-evidence-and-expert-opinion-on-thromboprophylaxis-after-total-knee-and-hip-replacement"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,25]]},"references-count":76,"URL":"https:\/\/doi.org\/10.7759\/cureus.51089","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,25]]}}}